Ação da terapia hormonal na Esclerose Lateral Amiotrófica: revisão sistemática

• Ano de defesa: 2019
• Autor(a) principal: Vasconcelos, Katia De [UNIFESP]
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal de São Paulo (UNIFESP)
• Palavras-chave em Português: Amyotrophic Lateral Sclerosis; Sex Hormones; Postmenopause,; Esclerose Amiotrófica Lateral; Hormônios Sexuais; Pós-Menopausa; Doença Dos Neurônios Motores; Terapia De Reposição Hormonal
• Link de acesso: https://sucupira.capes.gov.br/sucupira/public/consultas/coleta/trabalhoConclusao/viewTrabalhoConclusao.jsf?popup=true&id_trabalho=8006088; https://repositorio.unifesp.br/handle/11600/60053

Amyotrophic Lateral Sclerosis (ALS), a fatal disease characterized by muscle and fasciculations weakness and atrophy and decreased reflexes due to upper and lower motor neurons death. It can be present in both sexes (55-65 years), but with predominance in males. However, in female patients, ALS presents its first symptoms when they are already postmenopausal, when then the incidence ratio of the disease is practically equal between the sexes. Which leads to a probable involvement of sex hormones in the development and protection against ALS. The aim of this systematic review, which used the PRISMA consensus and NOS (New Casttle-Ottawa Scale) score, was to evaluate the evidence of the action of hormone therapy in women with ALS. The Medline and Cochrane databases were accessed from March 2019 to June 2019, and only full text articles in Spanish, English and Portuguese languages were included. Only four articles matched our inclusion criteria. Postmenopausal women who used exogenous estrogen did not have the same protective factor as women still under the action of endogenous estrogen in the same age group. There was also no increase in survival of these women.